Sanders D L, Shahid M K, Ahlijah B, Raitt J E, Kingsnorth A N
Department of Surgery, Derriford Hospital, Plymouth, PL6 8DH, UK.
Hernia. 2008 Dec;12(6):589-92; discussion 667-8. doi: 10.1007/s10029-008-0405-x. Epub 2008 Aug 13.
Guidelines and local hospital protocols dealing with anticoagulation at the time of surgery vary, but most suggest stopping Warfarin at least three days preoperatively with or without interim low-molecular-weight heparin or intravenous heparin infusion. This study addresses whether it is safe to perform inguinal hernia surgery on the patient who is fully anticoagulated with Warfarin.
We performed a retrospective case note analysis of consecutive patients who underwent elective inguinal hernia repair at the Plymouth Hernia Service between 1999 and 2007. All patients on therapeutic oral anticoagulation with Warfarin were selected. Data analysis was of complications and patient-related, hernia-related, and surgery-related variables. International normalising ratio (INR) was measured on the day preceding surgery.
A total of 49 patients had been operated on whilst anticoagulated with Warfarin. The mean age of the patients was 75 years (range 44-96 years). Thirty patients were on Warfarin for atrial fibrillation, seven for previous PE, three for previous DVT, and nine for mechanical heart valves. Forty patients had a desired INR range of 2-3, and nine a desired range of 3-4. Forty-five (91.8%) patients had no complications or mild bruising requiring no further management. Three (6.1%) patients developed haematomas requiring surgical management and there was one death of unrelated cause. An INR of greater than 3 increased the risk of postoperative haematoma (P = 0.03). None of the other measured patient-related, hernia-related, or surgery-related variables predicted complications (P > 0.05).
Patients can safely undergo inguinal hernia repair whilst on Warfarin as long as the INR is less than 3.
处理手术时抗凝问题的指南和当地医院方案各不相同,但大多数建议术前至少停用华法林三天,期间可使用或不使用低分子量肝素或静脉注射肝素。本研究探讨了对华法林完全抗凝的患者进行腹股沟疝手术是否安全。
我们对1999年至2007年在普利茅斯疝科接受择期腹股沟疝修补术的连续患者进行了回顾性病例记录分析。选取所有接受华法林治疗性口服抗凝的患者。对并发症以及与患者、疝和手术相关的变量进行数据分析。在手术前一天测量国际标准化比值(INR)。
共有49例患者在服用华法林抗凝期间接受了手术。患者的平均年龄为75岁(范围44 - 96岁)。30例患者因心房颤动服用华法林,7例因既往肺栓塞,3例因既往深静脉血栓形成,9例因机械心脏瓣膜。40例患者的目标INR范围为2 - 3,9例为3 - 4。45例(91.8%)患者无并发症或仅有无需进一步处理的轻度瘀伤。3例(6.1%)患者出现血肿需要手术处理,有1例因无关原因死亡。INR大于3会增加术后血肿的风险(P = 0.03)。其他所测量的与患者、疝和手术相关的变量均未预测到并发症(P > 0.05)。
只要INR小于3,患者在服用华法林期间可安全地进行腹股沟疝修补术。